

UNDER THE AUSPICES OF:



OCTOBER 16 > 18, 2023

# PANCREATIC CANCER SYMPOSIUM

DOMAINE DU HAUT-CARRE,  
UNIVERSITY OF BORDEAUX

[WWW.PCS-AFRCP.COM](http://WWW.PCS-AFRCP.COM)

## LOCAL ORGANIZING COMMITTEE

Samuel AMINTAS, Sandrine DABERNAT,  
Serge EVRARD, Majid KHATIB,  
Christophe LAURENT, Véronique VENDRELY,  
Simon PERNOT (Bordeaux)

## NATIONAL ORGANIZING COMMITTEE

Fabienne GUILLAUMOND (Marseille),  
Christèle LARBOURET (Montpellier),  
Nicolas JONCKHEERE (Lille),  
Jérôme CROS (Clichy), Louis BUSCAIL (Toulouse),  
Anca HENNINO (Marseille), Remy NICOLLE  
(Paris), Sophie VASSEUR (Marseille)

# PRELIMINARY PROGRAM

# EDITORIAL



Although pancreatic ductal adenocarcinoma (PDAC) represents less than 2% of new cancers, it is constantly increasing (14,000 new cases/year in France) and is one of the main causes of cancer-related mortality. Indeed, the vast majority of pancreatic cancers are locally advanced or metastatic at diagnosis. The incidence almost equal to the mortality rate proves the incurable nature of this cancer. Despite the progress made in understanding the pathogenesis of PDAC, and the improvement of treatment regimens, the survival rate after treatment remains poor. Thus, basic and clinical research is still the best allies of patients and medical teams to make significant breakthroughs and improve the prognosis of this dreaded disease. The **"Pancreatic Cancer symposium 2023"** will be the third edition of an international meeting that brings together researchers and clinicians at the forefront of knowledge of pancreatic cancer. It is organized by a non-profit group of French researchers (AFRCP). Considering recent state-of-the-art, this event will focus on current and future noteworthy themes in the field. In particular, the following interdisciplinary sessions will be proposed to the international research community: (I) new modalities for PDAC clinical management, (II) identification and targeting of new tumor vulnerabilities, (III) exploration of the primary and the secondary tumor microenvironment, (IV) new modalities and technologies for pancreatic cancer research, with a special round table on PDAC organoids, (V) PDAC prevention and early disease. A final session (VI) will be centered on the involvement of the patients in research design.

Organizing Committee



OCTOBER 16 > 18, 2023

# PANCREATIC CANCER SYMPOSIUM


DOMAINE DU HAUT-CARRE,  
UNIVERSITY OF BORDEAUX

WWW.PCS-AFRCP.COM

## PRELIMINARY PROGRAM



### MONDAY, OCTOBER 16<sup>TH</sup>


11.30  **REGISTRATION  
& WELCOME OF THE PARTICIPANTS**  
*Opening Symposium*  
by **Pr. Louis BUSCAIL**,  
President of the AFRCP, Toulouse  
University Hospital, France

12.00  **LUNCH BREAK**

#### SESSION I

#### NEW MODALITIES FOR PDAC CLINICAL MANAGEMENT

14.30  **OPENING CONFERENCE**  
History of pancreatic cancer  
and evolution cancer management  
By **Pr. Jean-Robert Delpero**,  
Institut J.Paoli et I.Calmettes,  
Marseille, France

15.10  **LECTURE**  
therapeutic innovation  
for metastatic cancer  
By **Pr. Pascal Hammel**, Hôpital  
Paul-Brousse, Villejuif, France

15.40  **LECTURE**  
Epidemiology France vs Europe,  
or Europe vs North America  
By **Pr. Isabelle Baldi**,  
ISPED, Bordeaux, France

16.10  **LECTURE**  
Stereotaxic radiotherapy  
By **Karine Hausterman**,  
UZ Leuven, Belgique  
  
The patient in the treatment  
strategy  
TBD

16.40  **COFFEE BREAK**

17.00  **END OF THE DAY**

# PRELIMINARY PROGRAM





**TUESDAY, OCTOBER 17<sup>TH</sup>**

08.30  **OPENING**

## SESSION II

### IDENTIFICATION AND TARGETING OF NEW TUMOR VULNERABILITIES

09.00  **CONFERENCE**  
New interdisciplinary technological  
approaches applied to the study  
of the tumor microenvironment  
*By Dr. Alex Shalek,*  
*Cambridge, MA, USA*

09.40  **LECTURE**  
The microbiota a new actor  
in the PDAC  
*By Pr. Cindy Neuzillet,*  
*Institut Curie, Paris France*

10.10  **Talk from abstracts**

10.20  **Talk from abstracts**

10.30  **Talk from abstracts**

10.40  **COFFEE BREAK**

11.10  **LECTURE**  
The promises of virotherapy  
*By Dr. Pierre Cordelier,*  
*CRCT, Toulouse, France*

11.40  **Talk from abstracts**

11.50  **Talk from abstracts**

12.00  **Talk from abstracts**

12.10  **LUNCH BREAK**

## SESSION III

### EXPLORATION OF THE PRIMARY AND SECONDARY TUMOR MICROENVIRONMENT

13.40  **CONFERENCE**  
Stroma and resistance  
*By Dr. Corinne Bousquet,*  
*CRCT, Toulouse, France*


14.20  **LECTURE**  
Multidisciplinary studies of stem  
cells and tumor heterogeneity  
*By Pr. Alex Behrens, Institute*  
*of Cancer research, London, UK*

14.50  **Talk from abstracts**

15.00  **Talk from abstracts**

15.10  **Talk from abstracts**

15.20  **COFFEE BREAK**

15.40  **LECTURE**  
Liver determinism of pancreatic  
cancer metastases  
*By Pr. Michael Schmid, University*  
*of Liverpool, Liverpool UK*

16.10  **Talk from abstracts**

16.20  **Talk from abstracts**

16.30  **Talk from abstracts**

16.40  **END OF THE DAY**

20.00  **GALA DINNER**

OCTOBER 16 > 18, 2023

**PANCREATIC  
CANCER  
SYMPOSIUM**  
**BORDEAUX**


## WEDNESDAY, OCTOBER 18<sup>TH</sup>

08.30  **OPENING**

### SESSION IV

#### NEW MODALITIES AND TECHNOLOGIES FOR PANCREATIC CANCER RESEARCH

09.00  **CONFERENCE**  
Genetic and chemical proteomic approaches to delineate the role of ROS during pancreatic tumorigenesis  
*By Dr. Christine Chio, Columbia University, New York, USA*


09.40  **LECTURE**  
Targeting of CD39 et CD73  
*By Pr. John Stagg, Université de Montréal, Montreal, Canada*

10.10  **Talk from abstracts**

10.20  **Talk from abstracts**

10.30  **Talk from abstracts**

10.40  **COFFEE BREAK**

11.10  **ROUND TABLE**  
Organoids as PDAC models  
*By Dr. Nathalie Vergnolle, Toulouse*  
*PDAC MODELS:*  
*Dr. Audrey Vincent, Lille,*  
*Dr. Nelson Duseti, Marseille,*  
*Dr. Fanny Jolin, Marseille*

11.40  **Talk from abstracts**


11.50  **Talk from abstracts**

12.00  **Talk from abstracts**

12.10  **LUNCH BREAK**

### SESSION V

#### PDAC PREVENTION AND EARLY DISEASE

13.40  **CONFERENCE**  
Early detection of pancreatic cancer  
*By Pr. Michael Goggins, The Johns Hopkins Hospital, Baltimore, MD, USA*


14.20  **LECTURE**  
New methods of early detection and the development of personalized therapies  
*By Pr. Dieter Saur, Central Institute for Translational Cancer Research, Munich, Germany*

14.50  **Talk from abstracts**

15.00  **Talk from abstracts**

15.10  **Talk from abstracts**

15.20  **COFFEE BREAK**

15.40  **LECTURE**  
Cancer prevention  
*By Dr. Nuria Malats, CNIO, Madrid, Spain*

16.10  **Talk from abstracts**

16.20  **Talk from abstracts**

16.30  **Talk from abstracts**

### SESSION VI

#### THE ROLE OF PATIENTS IN CANCER RESEARCH

16.40  **ROUND TABLE**  
Consideration of the patient in European research protocols  
*By Cyril Sarrauste, from the association patients en réseau with the DICE association,*



# CALL FOR ABSTRACTS



You are welcome to submit an abstract to present your experience and share your expertise.

Both AFRCP and non-AFRCP members are allowed to submit abstracts.

**Abstracts should be prepared as following:**

- An English language abstract must be in the terminology familiar to specialists.
- The text should be succinct and substantive. Beside presenter's full names and affiliations, the abstract must include purpose, methods, results, conclusion and significance.
- Submit a document no longer than 500 words. After consideration and selection by the scientific board, you will be notified if your abstract is considered for poster session or for both poster session and oral communication.

Please select the session in which you consider your abstract would be the most relevant. Nevertheless, scientific board retains the right to decide which session is the most appropriate.

## TUESDAY, OCTOBER 17<sup>TH</sup>

- **Session II**  
Identification and targeting of new tumor vulnerabilities (oral presentation)
- **Session III**  
Exploration of the primary and secondary tumor microenvironment (oral presentation)

## WEDNESDAY, OCTOBER 18<sup>TH</sup>

- **Session IV**  
New Modalities and Technologies for Pancreatic Cancer Research (oral presentation)
- **Session V**  
PDAC prevention and early disease (oral presentation)

**ABSTRACT SUBMISSION AND OPENING:**  
**TUESDAY, MARCH 20<sup>TH</sup>, 2023**


**DEADLINE FOR ABSTRACTS SUBMISSION:**  
**FRIDAY, SEPTEMBER 6<sup>TH</sup>, 2023**

**DETAILS AND SUBMISSION ON**  
[www.pcs-afrcp.com](http://www.pcs-afrcp.com)

# GENERAL INFORMATION



## INFORMATION & ORGANIZATION

**COM&CO, Johanna GAUDE** 

**POST** 15, Bd Grawitz  
13016 Marseille, France

**TEL** +33 (0)4 91 09 70 53

**FAX** +33 (0)4 96 15 33 08

**EMAIL** [j.gaude@comnco.com](mailto:j.gaude@comnco.com)

## CONGRESS VENUE

Domaine du Haut-Carré  
43 Rue Pierre Noailles  
33400 Talence

# REGISTRATION FORM



## TO BE RETURN TO:

POST COM&CO - 15, Bd Grawitz  
13016 Marseille, France

FAX +33 (0)4 96 15 33 08

EMAIL e.jarry@comnco.com  
j.gaude@comnco.com

REGISTRATION ONLINE ON [WWW.PCS-AFRCP.COM](http://WWW.PCS-AFRCP.COM)

☐ Pr ☐ Dr ☐ Mr ☐ Ms

Last name..... First name.....

Institution/Company.....

Department.....

Address.....

Post code..... City .....

Country .....

Phone..... Email .....

REGISTRATION FEES	EARLY BIRD FEES UNTIL JULY 31 <sup>ST</sup> 2023	LATE REGISTRATION
<input type="checkbox"/> UNDERGRADUATE & GRADUATE STUDENTS	150€	250€
<input type="checkbox"/> ACADEMIC AND CLINICIAN	400€	550€
<input type="checkbox"/> CORPORATE (BIOTECH)	500€	600€
<input type="checkbox"/> CONGRESS DINNER	65€	

## PAYMENT

☐ **BY CREDIT CARD (Visa, Mastercard (no other card))**, on protected payment Paybox online form, directly on the website [www.comnco.com](http://www.comnco.com). Please indicate your name + **PCS 2023** in the part : "Additional details".

☐ **BY CHECK ENCLOSED** (make check in euro payable in France to Com&Co)

☐ **BY BANK TRANSFER TO COM&CO EVENTS**

Bank: Société Marseillaise de Crédit - IBAN: FR76 3007 7048 8111 7988 0020 038 - BIC: SMCTFR2A

By registering to this congress, we warn you that you accept our general conditions of sale. You can read them here: [www.comnco.com/cgv](http://www.comnco.com/cgv)